Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cyfuse Biomedical KK's EBIT per Share for the
three
months ended in Dec. 2025 was 円0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円-50.61.
During the past 3 years, the average EBIT per Share Growth Rate was 16.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Cyfuse Biomedical KK's EBIT per Share or its related term are showing as below:
TSE:4892'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -19.8 Med: -1.85 Max: 16.1
Current: 16.1
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Cyfuse Biomedical KK was 16.10% per year. The lowest was -19.80% per year. And the median was -1.85% per year.
TSE:4892's 3-Year EBIT Growth Rate is ranked better than 62.98% of 813
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs TSE:4892: 16.10
Cyfuse Biomedical KK (TSE:4892) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Cyfuse Biomedical KK EBIT per Share Related Terms
Cyfuse Biomedical KK EBIT per Share Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-50.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyfuse Biomedical KK (TSE:4892) has a EBIT per Share of 円-50.61 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cyfuse Biomedical KK and its competitors. According to the industry distribution chart, Cyfuse Biomedical KK ranks #301 out of 813 companies in the Drug Manufacturers industry, placing it in the top 37%.
Is Cyfuse Biomedical KK's EBIT per Share too high?
Cyfuse Biomedical KK's current EBIT per Share is 円-50.61. Based on the distribution chart, Cyfuse Biomedical KK ranks #301 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cyfuse Biomedical KK has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #301 out of 813 companies for EBIT per Share. This puts Cyfuse Biomedical KK in the upper half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current EBIT per Share is 円-50.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,174.28, compared to a current price of 円527.00 — trading 75.8% below its estimated fair value. The current EBIT per Share is 円-50.61. Cyfuse Biomedical KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current EBIT per Share is 円-50.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円527.00 is trading 75.8% below its estimated GF Value™ of 円2,174.28.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for TSE:4892:
EBIT per Share: 円-50.61
GF Value™: 円2,174.28 vs. price of 円527.00 (75.8% below fair value)
No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
53GF Score
Get the complete analysis for TSE:4892
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4892 has been successfully added to your 
